
Tom Woiwode
Managing Director · Versant Ventures
Managing Director
Tom Woiwode has worked with Versant Ventures since 2002 in operational and investment roles and was promoted to Managing Director in 2014. He served as start-up CBO for Amira, Synosia and Flexion and as COO of Okairos, leading its acquisition process with GSK, and has since led multiple investments that reached liquidity. He was previously a medicinal chemist at XenoPort and earned his Ph.D. in chemistry from Stanford.
Board seats
99 current
· PUBLIC SOURCES
Credited hits
13
· PUBLIC SOURCES
Midas years
LAST CHECKED NOV 2026
Founder rating
LAST CHECKED NOV 2026
Maintained from public sources. Not claimed. If you're Tom Woiwode, you can claim this profile.
Claim this profileHow claiming worksClaiming verifies identity and affiliation. It does not permit editing reviews, scores, or cited facts.
Track record
- Flexion Therapeuticsipo
His Versant bio: he was start-up CBO for Flexion (2014 IPO).
Source: versantventures.com
- CRISPR Therapeuticsipo
His Versant bio: since becoming Managing Director he assumed the lead role in investments that reached liquidity including Crispr (2016 IPO).
Source: versantventures.com
- Audentes Therapeuticsipo
His Versant bio lists Audentes (2016 IPO) among lead-role investments that reached liquidity.
Source: versantventures.com
- Crinetics Pharmaceuticalsipo
His Versant bio lists Crinetics (2018 IPO) among lead-role investments that reached liquidity.
Source: versantventures.com
- Okairosacquired
His Versant bio: as COO of Okairos he led the process that culminated in the acquisition by GSK.
Source: versantventures.com
- Vividion Therapeuticsacquired
His Versant bio lists Vividion (sale) among lead-role investments that reached liquidity.
Source: versantventures.com
- Amira Pharmaceuticalsacquired
Start-up CBO; firm bio marks it a sale.
Source: versantventures.com
- Synosia Therapeuticsacquired
Start-up CBO; firm bio marks it a sale.
Source: versantventures.com
- Gritstone bioipo
Firm bio lists 2018 IPO among his lead-role investments.
Source: versantventures.com
- Jecure Therapeuticsacquired
Firm bio marks it a sale among his lead-role investments.
Source: versantventures.com
- Therachonacquired
Firm bio marks it a sale among his lead-role investments.
Source: versantventures.com
- Aligos Therapeuticsipo
Firm bio lists 2020 IPO among his lead-role investments.
Source: versantventures.com
- Passage Bioipo
Firm bio lists 2020 IPO among his lead-role investments.
Source: versantventures.com
Board seats
Current board seats · 9
- Adverum BiotechnologiesSource: versantventures.com
- Aligos TherapeuticsSource: versantventures.com
- AnokionSource: versantventures.com
- CODA BiotherapeuticsSource: versantventures.com
- Gritstone bioSource: versantventures.com
- Lycia TherapeuticsSource: versantventures.com
- Passage BioSource: versantventures.com
- Tempest TherapeuticsSource: versantventures.com
- Vividion TherapeuticsSource: versantventures.com
Success signals
Forbes Midas List
No public record
Not listed.
Reputation
No reputation score — basis not established for this investor.
No reputation sources on file yet.
Suggest a sourceContact
Published sources only
Published contact details collected from public sources. Not a referral, and not an introduction.
Published contact
- Website
- www.versantventures.com
Published sources only
GlassVC lists only contact information the firm or its sources have published. We do not list personal emails, direct lines, or private addresses.
Claimed profiles can replace or remove contact details.
What founders say
Founder-submitted · Verified identity and relationship
No founder reviews yet
Be the first founder to share your experience with Tom Woiwode. Reviews come from founders whose identity and relationship have been verified.
Write the first reviewFirm-level reviews are not attributed to Tom Woiwode.
Methodology
This profile carries no tier: tier belongs to the firm and is shown only via the linked firm name — never inherited onto a person.
Credited deals, board seats, Midas years and reputation links are carried per investor in the catalog, each item with the public source it was credited from, linked from the sections above. Fields with no sourced record render their honest null states, and every published field traces to the catalog record listed below. Review dimension scores appear only at three or more reviews.
Corrections with a source: Suggest a correction.
Source record 1
- [1]
DATABASE · GlassVC catalog — Catalog record for Tom Woiwode — provenance: GlassVC catalog
↩ cites: Title · Firm · Type · Bio · Location · Focus · Credited deals · Board seats
EVERY FIGURE ON THIS PAGE IS TRACEABLE TO THE CATALOG RECORD ABOVE · LAST CHECKED NOV 2026
